PUBLISHER: TechNavio | PRODUCT CODE: 1743430
PUBLISHER: TechNavio | PRODUCT CODE: 1743430
The diffuse large b-cell lymphoma (DLBCL) therapeutics market is forecasted to grow by USD 2,457.1 mn during 2024-2029, accelerating at a CAGR of 8.2% during the forecast period. The report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, increasing incidence of dlbcl, and increasing approval of therapeutics for patients with relapsed or refractory dlbcl.
Market Scope | |
---|---|
Base Year | 2025 |
End Year | 2029 |
Series Year | 2025-2029 |
Growth Momentum | Accelerate |
YOY 2025 | 7.6% |
CAGR | 8.2% |
Incremental Value | $2,457.1 mn |
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
Technavio's diffuse large b-cell lymphoma (DLBCL) therapeutics market is segmented as below:
By Product
By Application
By Therapy
By Geographical Landscape
This study identifies the technological advances as one of the prime reasons driving the diffuse large b-cell lymphoma (DLBCL) therapeutics market growth during the next few years. Also, increasing patient support programs and strategic alliances will lead to sizable demand in the market.
The report on the diffuse large b-cell lymphoma (DLBCL) therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diffuse large b-cell lymphoma (DLBCL) therapeutics market vendors that include AbbVie Inc., ADC Therapeutics SA, Amgen Inc., Bayer AG, BeiGene Ltd., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., Erytech Pharma SA, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the diffuse large b-cell lymphoma (DLBCL) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Exhibits: